Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...
The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities might be on hot button ...
beating the performance of the Medical sector with its loss of 3.78% and the S&P 500's gain of 0.22%. The investment community will be closely monitoring the performance of Eli Lilly in its ...
Zacks.com on MSN8d
Why the Market Dipped But Eli Lilly (LLY) Gained TodayIn the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
A proposed bill at the Indiana statehouse could mean anyone under the age of 16 could need to get parents approval before downloading social media apps. “We need the IEDC,” said State Senator ...
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback